The treatment of pyoderma gangrenosum using etanercept - 09/08/11
Plan
This case series was investigator initiated. Financial support for the manuscript was provided by Amgen Inc and by Wyeth Research. Conflicts of interest: Dr Roy has no conflicts of interest to disclose. Dr Conte has been a speaker for Amgen, Schering, Genentech, and Allergan. Dr Cohen has been a speaker for Amgen, Genentech, Novartis, and Glaxo, and has conducted research for Amgen, Genentech, 3M, Dermik, Galderma, and Medicis. Reprints not available from the authors. |
Vol 54 - N° 3S2
P. S128-S134 - mars 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?